Results per Page:
¿Necesito otra vacuna de refuerzo contra el SRAS-CoV-2?
Del Dr. Bo Zhang y laboratorios colaboradores, División de Vacunas y Enfermedades Infecciosas
Do I need another SARS-CoV-2 booster vaccine?
From Dr. Bo Zhang and collaborating labs, Vaccine & Infectious Disease Division
Vaccine targets that accommodate evolving SARS-CoV-2 variants
From the Overbaugh Lab, Human Biology and Public Health Sciences Divisions
The exclusion of immunocompromised patients in clinical trials and how we can do better
From Drs. Michael Boeckh, Joshua Hill, Steven Pergam and Larry Corey, Hematologic Malignancies and Cancer Immunology Programs of the Cancer Consortium
The curious case of ORF8: SARS-CoV-2 evolution is about more than just spike
From the Bedford Lab, Vaccine and Infectious Disease Division
A method to predict how a virus might spread through a population
From the Bedford Lab, Vaccine and Infectious Disease Division
La eficacia de la vacuna contra el virus SARS-CoV-2 en países de América Latina
Del Grupo Gilbert, Divisiones de Vacunas y Enfermedades Infecciosas y de Ciencias de la Salud Pública
Viral kinetics modeling for the current SARS-CoV-2 landscape
From the Schiffer Group, Vaccine and Infectious Disease Division
SARS-CoV-2 vaccine efficacy in Latin American countries
From the Gilbert Group, Vaccine and Infectious Disease and Public Health Sciences Divisions
Predicting endemic viruses engaged in an evolutionary battle with the immune system
From the Bedford Lab, Vaccine and Infectious Disease Division
Differential immune responses between mothers and their infants to SARS-CoV-2
From the Overbaugh and Lehman Groups, Human Biology Division
National study recommends starting SARS-CoV-2 mRNA vaccination three months after bone marrow transplant
Study involving 22 U.S. cancer centers and research institutions is one of the largest analyses of vaccination for any pathogen within the first year after bone marrow transplant
Is the microbiome a springboard or barrier to effective vaccination?
From the Kublin Lab, Vaccine and Infectious Disease Division
Leveling up SARS-CoV-2 neutralization assays
From the Bloom Lab, Basic Sciences and Public Health Sciences Divisions
Learning from the past to improve SARS-CoV-2 variant discovery
From Dr. Lue Ping Zhao and collaborating labs, Public Health Sciences, Clinical Research, and Vaccine and Infectious Disease Divisions
Community virus surveillance can double the data of vaccine trials
From Mr. Craig Magaret, Vaccine and Infectious Disease Division
The impact of antibodies to other coronaviruses on risk of SARS-CoV-2 infection in mothers and infants
From the Lehman and Overbaugh Labs, Human Biology Division
Tracking SARS-CoV-2 evolution one infection at a time
From the Bloom Lab, Basic Sciences Divisions, and the Greninger and Jerome Labs, Vaccine and Infectious Disease Division
Fauci visits Fred Hutch, discusses pandemics, vaccines and scientific misinformation
NIAID director’s determined spirit recognized with honorary Hutch Award
Are revisions to remdesivir dosing needed for treating SARS-CoV-2?
From the Schiffer lab, Clinical Research and Vaccine and Infectious Disease Divisions